Programme NCHIV21virtual
09:00 - 11:50 Session 1: Extinguishing Both Fires: HIV and COVID-19
| Session 1 | Extinguishing Both Fires: HIV and COVID-19 | |
|---|---|---|
| Chairs: Tania Mudrikova (UMC Utrecht) & Rogier Sanders (Amsterdam UMC) | ||
| 09:00 - 09:10 | Welcome and introductions | Marit van Gils, Peter Reiss, Kim Sigaloff (Board stichting NCHIV) |
| 09:10 - 09:30 | The path to find an HIV vaccine | Glenda Gray (University of the Witwatersrand, South Africa) |
| 09:30 - 09:50 | Moderated Q&A | |
| 09:50 - 09:55 | Short break | |
| 09:55 - 10:45 | Distinct antibody lineages with multiple specificities achieve neutralization breadth in an HIV-1 infected elite neutralizer | Jelle van Schooten (Amsterdam UMC) |
| People with HIV and suppressed viremia on ART are not at increased risk for acquiring SARS-CoV-2 infection | Myrthe Verburgh (Amsterdam UMC) | |
| Strong reduction in incidence of COVID-19-related hospitalization and death among people living with HIV in the Netherlands following the implementation of the national SARS-CoV-2 vaccination program | Ferdinand Wit (Stichting hiv monitoring) | |
| Cascade of care for people living with HIV in Aruba and Curaçao | Marlous Rodriguez (UMC Utrecht) | |
| Estimating the prevention potential of HIV infections in Amsterdam MSM, heterosexuals, and men and women with a migration background | Alexandra Blenkinsop (AIGHD; Imperial College London) | |
| Moderated Q&A | ||
| 10:45 - 11:00 | Break - Nigeria calling, Nwanneka Okere (AIGHD/Amsterdam UMC) | |
| 11:00 - 11:45 | SHM 2021 Monitoring Report in the spotlight | Ard van Sighem, Colette Smit & Ferdinand Wit (SHM) |
| Panel discussion 2021 NL Monitoring Report | Dinah Bons (Trans United Europe) Judith Branger (NVHB kwaliteitscommissie) Wilma Brokking (DC klinieken A'dam) Maria Prins (GGD A'dam) Moderator: Marc van der Valk (SHM) |
|
| 11:45 - 11:50 | Short break - Australia calling, Jori Symons (UMCU) | |
| 11:50 - 12:10 | Parallel spotlight sessions followed by a moderated Q&A (see separate dropdown session A) | |
| 12:10 - 12:15 | Short break - Kenya calling, Makobu Kimani (AIGHD/Amsterdam UMC & KEMRI Wellcome Trust, Kilifi) | |
| 12:15 - 12:35 | Parallel spotlight sessions followed by a moderated Q&A (see separate dropdown session B) | |
11:50 - 12:10 Parallel spotlight session A
12:15 - 12:35 Parallel spotlight session B
12:35 - 13:35 Lunch session
| Gilead | ||
| 12:35 - 12:50 | ART of Gilead: past, present and future | Joel Gallant (MD, MPH, Executive Director of Medical Affairs at Gilead Sciences) |
| 12:50 - 13:00 | Q&A | |
| MSD | ||
| TBA | ||
| ViiV | ||
| 12:35 -12:40 | Introduction | Bart Lammertink (Country Medical Lead ViiV Healthcare Netherlands) |
| 12:40 - 12:50 | ViiV’s commitment to the global fight against HIV | Interview with Deborah Waterhouse, Chief Executive Officer (CEO) ViiV Healthcare |
| 12:50 - 13:25 | Samenwerking tussen zorgverleners en de farmaceutische industrie: nuttig, noodzakelijk kwaad of nooit doen? (This session will be in Dutch) | De achtergrond, inhoud en praktische toepassing van de CGR Gedragscode, over samenwerking tussen zorgverleners en farmaceutische industrie, met Marloes Meddens-Bakker (advocaat) |
13:35 - 15:30 Session 2: Promises and Barriers Toward an HIV Cure
| Session 2 | Promises and Barriers Toward an HIV Cure | |
|---|---|---|
| Chairs: Godelieve de Bree (Amsterdam UMC) & Jori Symons (UMC Utrecht) & TBA | ||
| 13:35 - 13:40 | Intro | |
| 13:40 - 14:00 | The latest insights on the HIV viral reservoir: implications for curing HIV | Nicolas Chomont (University of Montreal, Canada) |
| 14:00 - 14:20 | Moderated Q&A | |
| 14:20 - 14:25 | Short break - ,Zimbabwe calling, Tom Jacobs (Radboudumc) | |
| 14:25 - 15:15 | Defining HIV-1’s doorway into the intestinal mucosa using an advanced human primary gut-epithelial-immune cell co-culture organoid model | Anusca Rader (Amsterdam UMC) |
| Continuous decline of intact proviral DNA after two decades of antiretroviral therapy | Marieke Nühn (UMC Utrecht) | |
| Identifying host genetic determinants of HIV-1 reservoir markers reveals PTDSS2, RNH1 and IRF7 as potential modifying factors in HIV-1 patients | Marc Blaauw (Radboudumc) | |
| Genetic variation in autophagy machinery is associated with enhanced antiviral T-cell immunity and reduced T-cell exhaustion signatures in HIV-1 infected individuals | Renee Schreurs (Amsterdam UMC) | |
| Trends in HIV Stigma Experienced by People with HIV in the Netherlands: A Comparison of Cross-sectional Surveys Over Time | Sarah Stutterheim (Maastricht University) | |
| Moderated Q&A | ||
| Break | ||
15:30 - 17:05 Session 3: The Changing Spectrum of ART
| Session 3 | The Changing Spectrum of ART | |
|---|---|---|
| 15:30 - 15:45 | Providing ART: a Personal Reflection | Sven Danner |
| 15:45 - 16:25 | Long-acting ART: a paradigm shift? (panel discussion) | Natasja van Holten (LUMC) Piter Oosterhof (OLVG) Cissy Kityo (JCRC, Kampala, Ugana) Edwin Oraki (perspective from a person living with HIV) Moderators: Bertus Tempert (Hiv vereniging) & Jet Gisolf (Rijnstate) |
| 16:25 - 16:30 | Short break - Ukraine calling, Marta Vasylyev (ErasmusMC & Astar Medical Center, Lviv) | |
| 16:30 - 16:50 | Parallel spotlight sessions followed by a moderated Q&A (see separate dropdown session C) | |
| 16:50 - 16:55 | Short break - Zimbabwe/Uganda/Zambia/S Africa calling, Hylke Waalewijn (Radboudumc) | |
| 16:55 - 17:05 | The Joep Lange and Jacqueline van Tongeren Young Investigator Award Ceremony | |
16:30 - 17:05 Parallel spotlight session C
17:05 - 18:00 Session 4: 40 Years of Aids
| Session 4 | 40 Years of Aids | |
|---|---|---|
| Interviewer Antoinnette Scheulderman (o.m. Volkskrant magazine) gaat in gesprek met Anne van de Laar (ervaringsdeskundige), Gloria Summerville (oprichtster Stichting Het Rode Lint), Mark Vermeulen (directeur Aidsfonds) en Peter Reiss (internist-onderzoeker). This session will be held in Dutch | ||
| 17:55 - 18:00 | Closing | |